Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 9;19(24):16518.
doi: 10.3390/ijerph192416518.

A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis

Natalia Turosz  1 , Kamila Chęcińska  2 , Maciej Chęciński  3 , Monika Kamińska  4 , Zuzanna Nowak  5 , Maciej Sikora  6   7 , Dariusz Chlubek  7
Affiliations

A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis

Natalia Turosz et al. Int J Environ Res Public Health. .

Abstract

Thiazolidinediones (TZDs) are a group of diabetes medications currently being investigated for anti-arthritis effectiveness, one of which is pioglitazone. The purpose of this scoping review is to evaluate the potential use of pioglitazone in the treatment of temporomandibular joint (TMJ) arthritis. The criteria of eligibility were studies with the diagnosis of arthritis and pioglitazone treatment with a change in any inflammation index as an outcome. Of the 1169 records initially identified following the selection process, two animal studies and four clinical studies were included in the review. Improvements from the baseline were observed in each treatment group for each inflammation indicator. The results of the animal studies on the temporomandibular joints and on patients with rheumatoid and psoriatic arthritis indicate that the drug in question may have potential to treat arthritis, including within the temporomandibular joint.

Keywords: arthritis; inflammation mediators; pioglitazone; temporomandibular joint; thiazolidinediones.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Initial and final values of tender joint count (TJC).
Figure 3
Figure 3
Initial and final values of swollen joint count (SJC).
Figure 4
Figure 4
Initial and final values of C-reactive protein (CRP) [mg/L].
Figure 5
Figure 5
Initial and final values of erythrocyte sedimentation rate (ESR) [mm/h].
Figure 6
Figure 6
The initial and final value of the visual analog scale (VAS) pain.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Corigliano D.M., Syed R., Messineo S., Lupia A., Patel R., Reddy C.V.R., Dubey P.K., Colica C., Amato R., De Sarro G., et al. Indole and 2,4-Thiazolidinedione Conjugates as Potential Anticancer Modulators. PeerJ. 2018;6:e5386. doi: 10.7717/peerj.5386. - DOI - PMC - PubMed
    1. Day C. Thiazolidinediones: A New Class of Antidiabetic Drugs. Diabet. Med. 1999;16:179–192. doi: 10.1046/j.1464-5491.1999.00023.x. - DOI - PubMed
    1. Yekta R., Dehghan G., Rashtbari S., Sadeghi L., Baradaran B., Sheibani N., Moosavi-Movahedi A.A. The Impact of Water Molecules on Binding Affinity of the Anti-Diabetic Thiazolidinediones for Catalase: Kinetic and Mechanistic Approaches. Arch. Biochem. Biophys. 2019;664:110–116. doi: 10.1016/j.abb.2019.02.002. - DOI - PubMed
    1. Consoli A., Formoso G. Do Thiazolidinediones Still Have a Role in Treatment of Type 2 Diabetes Mellitus? Diabetes Obes. Metab. 2013;15:967–977. doi: 10.1111/dom.12101. - DOI - PubMed
    1. Bundhun P.K., Janoo G., Teeluck A.R., Huang F. Adverse Drug Effects Observed with Vildagliptin versus Pioglitazone or Rosiglitazone in the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. BMC Pharmacol. Toxicol. 2017;18:66. doi: 10.1186/s40360-017-0175-0. - DOI - PMC - PubMed

Publication types

MeSH terms